CLPBY:OTO-Coloplast A/S ADR (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC Pink

Last Closing

USD 12.71

Change

+0.17 (+1.39)%

Market Cap

USD 14.82B

Volume

1.51M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Coloplast A/S develops and markets products and services that make life easier for people with private and personal medical conditions. The Company supplies its products to hospitals, institutions as well as wholesalers and pharmacies.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

N/A

USD 104.29B
ESLOY Essilor International SA

N/A

USD 103.38B
HOCPY Hoya Corp

N/A

USD 42.89B
HOCPF HOYA Corporation

N/A

USD 39.93B
RSMDF Resmed Inc DRC

N/A

USD 30.47B
CLPBF Coloplast A/S

N/A

USD 27.55B
TRUMF Terumo Corporation

N/A

USD 26.63B
TRUMY Terumo Corp ADR

N/A

USD 24.99B
SAUHF Straumann Holding AG

N/A

USD 22.13B
SDMHF Sartorius Stedim Biotech S.A

N/A

USD 21.40B

ETFs Containing CLPBY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.23% 78% C+ 64% D
Dividend Return 0.62% 38% F 11% F
Total Return 10.86% 75% C 64% D
Trailing 12 Months  
Capital Gain 0.63% 66% D+ 59% D-
Dividend Return 2.41% 80% B- 32% F
Total Return 3.05% 68% D+ 58% F
Trailing 5 Years  
Capital Gain 17.14% 71% C- 71% C-
Dividend Return 12.98% 67% D+ 43% F
Total Return 30.13% 71% C- 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 1.20% 37% F 44% F
Dividend Return 3.23% 37% F 42% F
Total Return 2.03% 80% B- 47% F
Risk Return Profile  
Volatility (Standard Deviation) 21.36% 68% D+ 53% F
Risk Adjusted Return 15.12% 42% F 37% F
Market Capitalization 14.82B 93% A 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.